Human HAV-IgG ELISA Kit is an enzyme linked-immunosorbent assay (ELISA) for qualitative detection of IgG-class antibodies to hepatitis A virus in human serum or plasma. It is intended for use in clinical laboratories for diagnosis and monitoring of patients related to infection with hepatitis A virus.
Contents of Kit
1. Microwell plate
2. Negative control
3. Positive control
5. Wash buffer
6. Chromogen solution a
7. Chromogen solution b
8. Stop solution
The components of the kit will remain stable through the expiration date indicated on the label and package when stored between 2-8°C, do not freeze. To assure maximum performance of the Human HAV-IgG ELISA Kit, during storage, protect the reagents from contamination with microorganism or chemicals.
The clinical sensitivity of this kit has been determinated by testing samples obtained from 2432 (1092 children and 1410 adults) individuals suspected for infection with HAV or recovered after outcome. Another group of samples obtained from 2180 healthy individuals was tested to determinate the clinical specificity of the assay. These studies were carried out in direct comparison with another commercially available HAV-IgG ELISA kit used as a confirmation assay. The evaluation results are given below.
Hepatitis A is a self-limited disease and chronic stage or other complications are rare. Infections occur early in life in areas with poor sanitation and crowded living conditions. With improved sanitation and hygiene, infections are delayed and consequently the number of persons susceptible to the disease increases. Because the disease is transmitted through the fecal-oral route, in dense populated regions an outbreak can arise from single contaminated source. The cause of hepatitis A is hepatitis A virus (HAV) - non enveloped positive strand RNA virus with a linear single strand genome, encoding for only one known serotype. HAV has four major structural polypeptides and it localizes exclusively in the cytoplasm of human hepatocytes. The infection with HAV induces strong immunological response and elevated levels, first of IgM and then IgG are detectable within a few days after the onset of the symptoms. The serological detection of HAV antibodies is an important marker for confirming infection phase with HAV, classification of the virus and identifying the source of infection.